Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.Zhenggang Ren, Stephen L. Chan, Zhiqiang Meng et al.|Journal of Clinical Oncology|2023Cited by 25
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.Ye Guo, Jin Li, Chunwang Yuan et al.|Journal of Clinical Oncology|2023Cited by 11